

## Eli Lilly's and Regeneron's mAb EUA Talk Trigger Expert Prudence on Available COVID-19 Data; Clinical Trials Likely to Be Affected if EUAs Come Through

October 9, 2020

### ATTORNEYS

Landmon, Chad

### PRACTICE AREAS

FDA

Intellectual Property

Manasi Vaidya

*GlobalData*

Axinn partner Chad Landmon was quoted in the *GlobalData* article, "Eli Lilly's and Regeneron's mAb EUA Talk Trigger Expert Prudence on Available COVID-19 Data; Clinical Trials Likely to Be Affected if EUAs Come Through."

Click [here](#) to access the article with the permission of "Investigative News team at GlobalData."